Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes
BMEA•Enrollment completed in phase II trial
Aug. 24 (Reuters) - Biomea Fusion, Inc. BMEA.O:
- Biomea Fusion announces completion of enrollment in the Covalent-211 Phase II trial of icovamenib in insulin-deficient type 2 diabetes.
- Topline 26-week primary endpoint data from Covalent-211 are expected in Q1 2027.
Source text: ID:nGNX6txzk7
Further company coverage: BMEA.O
